Effect of beta blockers in acute and chronic coronary syndromes without reduced ejection fraction: a landmark analysis from the REBOOT trial
European Heart Journal - Cardiovascular Pharmacotherapy
Should we reevaluate the prescription of beta-blockers post myocardial infarction (MI)?
The landmark analysis of the REBOOT trial suggests that patients with a mildly reduced LVEF (41-49%) who were prescribed a beta-blocker had numerically, but not statistically, lower event rates in the first year post MI compared with those who were not.
However, overall there was no improvement in clinical outcomes in patients with or without betablockers in the ACS (<1 year post MI) or event free CCS (>1 year post MI) groups. Explore the results and conclusions of this landmark study.
